Does Ketamine Show Up on a Drug Test? An Honest Answer (2026)

If you have a job that drug-tests, a custody case, a security clearance, a fitness-for-duty review, or any pending lab work, you deserve a clear answer before starting treatment.

The short version: standard drug tests do not screen for ketamine. The longer version has a few specific exceptions worth knowing.

The short answer

Standard drug tests do not include ketamine. The federal mandatory testing panel (used for DOT, federal employees, and most employer pre-employment screens) covers five substance classes: marijuana, cocaine metabolites, amphetamines (including MDMA), opiates and opioids (fentanyl was added effective July 7, 2025), and PCP. Ketamine is not on that list. Ten-panel tests add benzodiazepines, barbiturates, methadone, and a few others; ketamine is still not on them.

If you are screened for ketamine specifically, it will be on a specialized expanded panel ordered for a reason. Those situations include forensic toxicology after an accident, addiction medicine treatment monitoring, certain professional licensing boards (some state medical and nursing boards), and a small number of employer programs that elect a custom expanded panel.

When you might still be tested for ketamine

A few scenarios where it can come up:

• Forensic toxicology ordered after a motor-vehicle accident, sudden death, or criminal proceeding
• Addiction medicine treatment monitoring if you are in a substance-use treatment program that requires it
• Some state professional licensing boards (notably medical, nursing, and pilot boards) that maintain monitoring programs for impaired professionals
• Court-ordered testing in custody cases where a parent's medication use is being evaluated
• Specific employer programs that elect a custom expanded panel; uncommon, but it happens in some safety-sensitive roles
• Hospital admission and emergency-room toxicology to inform clinical care, especially around altered mental status or accident presentations

If you are in any of these situations, you should disclose your ketamine prescription proactively. A documented, physician-prescribed therapeutic ketamine course is fundamentally different from recreational use, and the disclosure resolves the question before it becomes a problem.

The PCP cross-reactivity question

This is the part that has caused some confusion in older internet posts. PCP (phencyclidine) and ketamine are both NMDA-antagonist dissociatives with similar molecular structure, and there has been concern that ketamine could trigger a false-positive PCP result on the immunoassay screen.

The current evidence does not support that concern for pharmaceutical ketamine on modern assays. In a head-to-head 2019 study, Gomila and colleagues tested ketamine against five commercial PCP immunoassays and found that ketamine itself did not produce a positive result on any of them. What did cross-react were illicit ketamine analogues (designer drugs like 3-MeO-PCP and 4-MeO-PCP), which are different chemicals from your prescription medication.

That said, two practical points still matter:

1. Older immunoassays and isolated case reports in the older literature have suggested cross-reactivity. If your test uses an older or unusual platform, the result may differ.
2. Confirmatory testing distinguishes them definitively. If a PCP screen comes back unexpectedly positive, the standard follow-up is gas-chromatography mass-spectrometry (GC-MS), which separates ketamine and PCP by molecular structure. Always request a confirmatory test before any consequence is assigned to a positive screen.

If you want to read more about this in the primary literature, the Gomila 2019 paper is in the References section below.

How long ketamine stays detectable (when the test does include it)

If the panel does include ketamine, the detection window depends on dose, frequency, and which test is being run.

The norketamine metabolite is the persistent one. It is what gives the longer urine window even after a single therapeutic dose. Patients on weekly or biweekly maintenance dosing should expect a continuous low-level positive on any test that specifically targets ketamine, in either compound.

This applies to any ketamine product: racemic ketamine compounded for at-home sublingual use, IV ketamine in a clinic, or Spravato (esketamine) administered intranasally. The body metabolizes them to the same family of compounds.

How to disclose if you have to

The right time to disclose is before the test, not after. Most testing programs have a pre-test medication review where you can document any prescription medications. Bringing documentation with you avoids the awkward "wait, what is this" conversation.

What to bring:

• A copy of your active prescription, ideally on your prescriber's letterhead
• Your prescriber's contact information (so the testing facility's medical review officer can verify if needed)
• A short, factual note explaining you are in a physician-supervised therapeutic ketamine program for a documented medical condition

A typical disclosure note can be brief:

Patient is in active treatment with prescription ketamine under physician supervision for [diagnosis]. Treatment is at therapeutic sublingual doses on a documented schedule. Please contact the prescribing physician at [phone/email] for verification.

Most occupational medicine reviewers are familiar with how this works for any prescribed medication that might appear on a screen. The process is the same as it would be for an employee taking prescribed Adderall, opioids for chronic pain, or a benzodiazepine: disclosure resolves it.

What about Spravato specifically?

Spravato is FDA-approved esketamine (S-ketamine), administered as a nasal spray in a certified clinic. Because it is FDA-approved with a defined indication for treatment-resistant depression, the documentation trail is even cleaner. Spravato will produce the same detection pattern as compounded ketamine on any test that targets the molecule, and the disclosure framework is identical. See Spravato vs. compounded ketamine for the broader comparison.

What about employer policies that ban "all controlled substances"?

Ketamine is a Schedule III controlled substance. Some employer policies are written broadly enough to cover any controlled substance use, including legitimately prescribed ones. In practice, most employers and most state laws distinguish between unauthorized use and a documented physician-prescribed therapeutic course. The Americans with Disabilities Act offers some protection where the underlying treated condition qualifies as a disability, though the legal terrain varies and is outside what your physician can advise on.

If your employer's policy is unusually strict, the right step is to consult with HR and, if needed, an employment attorney before starting treatment, not after. Discreet treatment exists in part because patients do navigate this question; choosing the right setting (at-home, evening sessions, weekend dosing) is part of how the at-home model accommodates working professionals.

What happens if a test comes back positive when it shouldn't have

If your standard PCP screen comes back positive and you are taking prescription ketamine:

1. Do not panic. The screen is not the final result. Confirmatory testing is the next step.
2. Request the confirmatory GC-MS test. This will distinguish ketamine from PCP definitively. You have the right to request confirmation before any employment or legal action.
3. Disclose your prescription to the medical review officer (MRO), the staff member at the testing program responsible for reviewing positive results in light of medications. This is what they are there for.
4. Provide your prescription documentation. A short call between the MRO and your prescriber typically resolves it within a day.

The MRO's role exists specifically to prevent legitimately prescribed medications from causing employment consequences. Use it.

Frequently Asked Questions

Will my pre-employment drug test detect ketamine?

Almost certainly not. Pre-employment screens almost always use either the standard 5-panel (federal SAMHSA panel) or a 10-panel test, neither of which includes ketamine. If your prospective employer uses an unusual expanded panel that includes ketamine, you will typically be told in advance. Disclose your prescription before testing if asked.

Does ketamine show up as PCP on a drug test?

Generally no, on modern PCP immunoassays. A 2019 study (Gomila et al., PMID 31329888) tested ketamine against five commercial PCP immunoassay platforms and found no cross-reactivity. Some older assays and isolated case reports have shown false positives, and illicit ketamine analogues do cross-react. Confirmatory GC-MS testing distinguishes ketamine from PCP definitively, so any positive screen should be confirmed before any consequence.

How long does ketamine stay in your system on a drug test?

If ketamine is specifically tested, urine windows are roughly 2 days for ketamine itself and up to 14 days for the norketamine metabolite (Adamowicz & Kala 2005, PMID 16105264). Blood is shorter (around 24 hours). Hair follicle testing detects 90 days or longer. Most tests, including standard 5-panel and 10-panel, do not test for ketamine at all, so these windows are only relevant if you are on an expanded or specialized panel.

Will Spravato show up on a drug test?

Same answer as compounded ketamine. Standard panels do not screen for it. Specialized panels that screen for ketamine will detect both Spravato (esketamine) and compounded racemic ketamine since they metabolize to the same compounds. The disclosure framework is identical.

Can I be fired for taking prescription ketamine?

Generally no, when the prescription is legitimate, documented, and you can show a physician-supervised therapeutic course. Most employer drug-testing policies distinguish between unauthorized substance use and prescribed medications. The Americans with Disabilities Act provides some protection where the treated condition qualifies as a disability. State laws vary. If your specific situation involves a strict policy or a safety-sensitive role, consult HR and an employment attorney before starting treatment, not after.

What about custody cases or family-court testing?

Family courts sometimes order specialized expanded panels that include ketamine. If you are in a custody proceeding or anticipating one, disclose your prescription to your attorney and bring documentation of your physician-supervised treatment. A documented, prescribed therapeutic course for a diagnosed condition is generally not held against a parent in the way unauthorized substance use is, but this is jurisdiction-specific and worth discussing with your attorney.

Do CDL drug tests include ketamine?

Federal Department of Transportation (DOT) testing for CDL holders follows the standard SAMHSA panel: marijuana, cocaine, amphetamines, opiates/opioids (including fentanyl as of July 7, 2025), and PCP. Ketamine is not on the federal panel. Some employers in safety-sensitive roles add additional substances; check with your employer's medical review officer if you are uncertain.

Should I tell my doctor I am being drug tested?

Yes. Mention it on your intake or any follow-up so your prescribing physician can document the medication clearly and provide a verification letter if you need one. We see a meaningful number of patients who work in drug-tested professions. The documentation is straightforward.

The bottom line

For the vast majority of patients on prescription ketamine therapy, drug testing is not a barrier. Standard panels do not screen for it, the PCP cross-reactivity concern is largely outdated for modern assays, and the small number of situations where ketamine is specifically tested are situations where proactive disclosure with documentation resolves it cleanly.

If you have a specific testing situation you are worried about (a custody case, a security clearance, a professional licensing review, a strict employer policy), bring it up on your intake. The at-home model is designed to fit around working life, and the documentation trail is part of what we provide.

If you are in Florida or New Jersey and want a careful evaluation of whether at-home ketamine therapy fits your situation, including documentation for any drug-testing context, the five-minute eligibility check is the start. For a sense of how the program actually runs day to day, see how at-home ketamine therapy works.

Dr. Ben Soffer

References

1. Gomila I, Leciñena MÁ, Elorza MÁ, Pastor Y, Sahuquillo L, Servera M, et al. Detectability of Dissociative Psychoactive Substances in Urine by Five Commercial Phencyclidine Immunoassays. J Anal Toxicol. 2019;43(6):497-503. PubMed: 31329888 Head-to-head testing of pharmaceutical ketamine and several illicit ketamine analogues against five commercial PCP immunoassays. Pharmaceutical ketamine produced no positive results on any of the five assays. Illicit analogues (3-MeO-PCP, 4-MeO-PCP, 2-oxo-PCE) did cross-react. The basis for the modern-assay reframing in this post.

2. Skaugen JM, Scoccimarro A, Pizon AF, Rymer JA, Giannoutsos S, Ekins S, et al. Novel ketamine analogues cause a false positive phencyclidine immunoassay. Ann Clin Biochem. 2019;56(5):598-607. PubMed: 31154806 Companion paper documenting which specific ketamine-related designer drugs do produce false-positive PCP screens. Confirms that the cross-reactivity issue is with illicit analogues, not pharmaceutical ketamine.

3. Adamowicz P, Kala M. Urinary excretion rates of ketamine and norketamine following therapeutic ketamine administration: method and detection window considerations. J Anal Toxicol. 2005;29(5):376-382. PubMed: 16105264 Direct study of urinary excretion patterns following therapeutic ketamine administration. The basis for the urine detection windows cited in this post: ketamine up to 2 days, norketamine metabolite up to 14 days even after a single therapeutic dose.

4. Peltoniemi MA, Hagelberg NM, Olkkola KT, Saari TI. Ketamine: A Review of Clinical Pharmacokinetics and Pharmacodynamics in Anesthesia and Pain Therapy. Clin Pharmacokinet. 2016;55(9):1059-1077. PubMed: 27028535 General PK reference covering ketamine and norketamine metabolism via CYP3A4 and CYP2B6. Background reading for the metabolism behind the detection windows.

5. Substance Abuse and Mental Health Services Administration (SAMHSA). Drug-Free Workplace Program: federal workplace drug testing guidelines and resources. samhsa.gov/substance-use/drug-free-workplace. Federal regulatory reference for what is and is not on the standard federal drug-testing panel. Confirms ketamine is not included; the panel covers marijuana, cocaine, amphetamines/MDMA, opiates/opioids (fentanyl added effective July 2025), and PCP. SAMHSA's Drug-Free Workplace page is the institutional landing for the Mandatory Guidelines for Federal Workplace Drug Testing Programs.